AMLX - NASDAQ
Amylyx Pharmaceuticals, Inc.
$13.61
+2.4%Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotAmylyx Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Amylyx Pharmaceuticals, Inc. Income Statement
AMLX • NASDAQ
| Amylyx Pharmaceuticals, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
0.0 | 87.4M | 380.8M | 22.2M | 0.0 | 650K | 1.4M | |
GROSS PROFIT | |||||||
(525K) | (42.2M) | (25.4M) | (3M) | (0.0) | (24.6M) | (11.9M) | |
-525K | 45.2M | 355.3M | 19.2M | 0.0 | -23.9M | -10.5M | |
OPERATING INCOME | |||||||
(152.8M) | (359.9M) | (316.5M) | (220.6M) | (82.7M) | (15.1M) | (13.6M) | |
(62.9M) | (114.3M) | (188.4M) | (127.1M) | (38.9M) | (15.1M) | (3.1M) | |
(90.4M) | (104.1M) | (128.2M) | (93.5M) | (44M) | (24.6M) | (11.9M) | |
-153.3M | -314.7M | 38.8M | -201.3M | -82.7M | -39M | -13.6M | |
PRE-TAX INCOME | |||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (2.3M) | (1.3M) | |
9.3M | 13.8M | 16.2M | 4.3M | 36K | -2.3M | -1.1M | |
(0.0) | (141.5M) | (0.0) | (0.0) | -285K | -24.6M | -1.4M | |
8.6M | 12.6M | 15.5M | 3.7M | -5.2M | -3.3M | -162K | |
-144.7M | -302.1M | 54.3M | -197.6M | -87.9M | -42.3M | -13.7M | |
NET INCOME | |||||||
(46K) | -393K | (5M) | (774K) | (0.0) | (0.0) | (0.0) | |
-144.7M | -301.7M | 49.3M | -198.4M | -87.9M | -42.3M | -14.8M |
SEC Filings
AMLX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 03, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 10, 2025 | September 09, 2025 | 2025 |
Related Guides
Continue your AMLX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.